Inflamed tumors respond favorably to immune checkpoint blockade (ICB) therapy and are characterized by an abundance of tumor infiltrated lymphocytes (TILs) enriched for interferon-γ (IFN-γ)-expressing CD8+ T cells, expression of checkpoint markers including programmed death-1 ligand 1 (PD-L1) and high mutational burden. Here, IFNG is linked to neoplasm.